Fig. 6

Associations between CAR-T cell expansion, sustained MRD negativity, survival outcomes, and influencing clinical factors. (A) Peak CAR-T-cell expansion in patients with sustained MRD negativity versus those with MRD positivity. (B, C) Area under the curve (AUC) for transgene levels from infusion to 28 days (AUC0–28d) and to the last recorded day (AUC 0–last day) in patients with sustained MRD negativity versus MRD positivity. (D) Univariate analysis of MRD negativity and CAR-T-cell persistence. (E) Univariate analysis of PFS and CAR-T-cell persistence. (F) Univariate analysis of OS and CAR-T-cell persistence. (G) Peak CAR-T cell expansion across different best response. (H) Peak CAR-T cell expansion in patients with or without previous ASCT. Spearman correlation coefficients (r) and corresponding p values are provided. ASCT, autologous haematopoietic stem cell transplantation; CAR, chimeric antigen receptor; CR, complete response; Mo, month; MRD, minimal residual disease; PR, partial response; VGPR, very good partial response